533
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States

ORCID Icon, , , , , , , , & show all
Pages 699-710 | Received 06 Mar 2020, Accepted 30 Jul 2020, Published online: 14 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Nicole M Engel-Nitz, Mary G Johnson, Michael P Johnson, Ashley S Cha-Silva, Samantha K Kurosky & Xianchen Liu. (2023) Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient Preference and Adherence 17, pages 1049-1062.
Read now

Articles from other publishers (2)

Ravi K. Goyal, Hua Chen, Susan M. Abughosh, Holly M. Holmes, Sean D. Candrilli & Michael L. Johnson. (2023) Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study. Cancer 129:7, pages 1051-1063.
Crossref
Ravi K. Goyal, Holly M. Holmes, Hua Chen, Susan Abughosh, Sean D. Candrilli & Michael L. Johnson. (2023) Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States. Breast Cancer Research and Treatment 198:1, pages 159-166.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.